Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...

Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug ...

Osvyrti is suppled as a 60mg/mL single-dose prefilled syringe for SC administration and Jubereq is supplied as 120mg/1.7mL single-dose vial for SC administration.

Regeneron announced the FDA’s approval of two indications of Eylea HD, including an 8mg injection for patients with macular ...

New 733-square-meter office will allow Deciphera to strategically expand its operations and further advance its commercial reach in Europe Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; ...

Jane Johnson spends her time in retirement immersed in a unique pastime – painting – and, while painting may not seem like an ...

Johnson & Johnson › Johnson & Johnson's (NYSE: JNJ) stock price is up more than 7% since the first trading day of November.

Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a ...

Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant's oncology pipeline.

Johnson & Johnson (NYSE: JNJ) shares began Monday higher in price. The pharmaceutical giant announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a ...

With sales exceeding US$146 billion over the past decade, U.S. pharmaceutical giant Merck’s Keytruda has become the ...

A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune ...